Precede
Boston, US · 2 known investors
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.
AI & Machine LearningBiotechDigital Health
Founders & leadership
RV
Rehan VerjeeCo-Founder, Chief Executive Officer, Board Director
SB
Sylvan BacaCo-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute
TC
Toni ChoueiriCo-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute
MF
Matthew FreedmanCo-Founder; Professor of Medicine, Dana-Farber Cancer Institute
Investors · 2
In the news
- Precede Biosciences Raises $83.5M in Financing | citybizcitybiz.co · 2026
- Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform - BioSpacebiospace.com · 2026
- Medpathtrial.medpath.com · 2026
- Precede Biosciences Emerges From Stealth With $57M in Fundingfinsmes.com · 2023
- Who We Are - Precede Capital Partnersprecedecapital.com · 2021